US5298605A
(en)
*
|
1986-10-08 |
1994-03-29 |
Regents Of The University Of Minnesota |
Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof
|
GB8709871D0
(en)
*
|
1987-04-27 |
1987-06-03 |
Turner R C |
Peptides
|
US5266561A
(en)
*
|
1988-01-11 |
1993-11-30 |
Amylin Pharmaceuticals, Inc. |
Treatment of type 2 diabetes mellitus
|
US5405831A
(en)
*
|
1989-07-08 |
1995-04-11 |
Amylin Pharmaceuticals, Inc. |
Treatment of bone disorders
|
GB8915712D0
(en)
*
|
1989-07-08 |
1989-08-31 |
Macintyre Iain |
Medical treatment
|
JP2533726Y2
(ja)
*
|
1990-07-23 |
1997-04-23 |
船井電機株式会社 |
記録再生機器
|
US5260275A
(en)
*
|
1990-08-14 |
1993-11-09 |
Amylin Pharmaceuticals, Inc. |
Hypoglycemics
|
US5527771A
(en)
*
|
1991-01-10 |
1996-06-18 |
Amylin Pharmaceuticals, Inc. |
Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
|
US5321008A
(en)
*
|
1991-01-10 |
1994-06-14 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
|
US5234906A
(en)
*
|
1991-01-10 |
1993-08-10 |
Amylin Pharmaceuticals, Inc. |
Hyperglycemic compositions
|
HU222249B1
(hu)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
WO1992015317A1
(en)
*
|
1991-03-08 |
1992-09-17 |
Amylin Pharmaceuticals, Inc. |
Synthetic preparation of amylin and amylin analogues
|
EP0503827A1
(en)
*
|
1991-03-15 |
1992-09-16 |
Pfizer Inc. |
Amylin and calcitonin gene-related peptide use and antagonists thereof
|
US5814600A
(en)
*
|
1991-05-24 |
1998-09-29 |
Amylin Pharmaceuticals Inc. |
Method and composition for treatment of insulin requiring mammals
|
DK0586589T3
(da)
*
|
1991-05-24 |
1997-09-22 |
Amylin Pharmaceuticals Inc |
Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande
|
ATE197764T1
(de)
*
|
1991-05-24 |
2000-12-15 |
Amylin Pharmaceuticals Inc |
Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
|
US5580953A
(en)
*
|
1991-08-14 |
1996-12-03 |
Amylin Pharmaceuticals, Inc. |
Amylin antagonist peptides and uses therefor
|
US6011068A
(en)
*
|
1991-08-23 |
2000-01-04 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US5858684A
(en)
*
|
1991-08-23 |
1999-01-12 |
The Brigham And Women's Hospital, Inc. |
Method of screening calcium receptor-active molecules
|
US6031003A
(en)
*
|
1991-08-23 |
2000-02-29 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US5763569A
(en)
*
|
1991-08-23 |
1998-06-09 |
The Brigham And Women's Hospital, Inc |
Calcium receptor-active molecules
|
US6001884A
(en)
*
|
1991-08-23 |
1999-12-14 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US6313146B1
(en)
|
1991-08-23 |
2001-11-06 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US5688938A
(en)
*
|
1991-08-23 |
1997-11-18 |
The Brigham & Women's Hospital, Inc. |
Calcium receptor-active molecules
|
CA2100745C
(en)
*
|
1991-11-19 |
2007-07-31 |
Laura S. L. Gaeta |
Amylin agonist peptides and uses therefor
|
WO1993019774A1
(en)
*
|
1992-04-03 |
1993-10-14 |
Amylin Pharmaceuticals, Inc. |
Amylin and possibly insulin containing composition for the treatment of anorexia and related states
|
WO1994003491A1
(en)
*
|
1992-08-06 |
1994-02-17 |
Pfizer Inc. |
Amylin muteins
|
US5376638A
(en)
*
|
1992-09-01 |
1994-12-27 |
Amylin Pharmaceuticals, Inc. |
Methods for treating renin-related disorders with amylin antagonists
|
US5545672A
(en)
*
|
1993-02-11 |
1996-08-13 |
The University Of Texas System |
Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
|
US5962314A
(en)
*
|
1993-02-23 |
1999-10-05 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
HU225496B1
(en)
*
|
1993-04-07 |
2007-01-29 |
Scios Inc |
Pharmaceutical compositions of prolonged delivery, containing peptides
|
US6114304A
(en)
|
1993-09-07 |
2000-09-05 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
KR950007873A
(ko)
*
|
1993-09-20 |
1995-04-15 |
후꾸하라 요시하루 |
생리 활성 물질 지속 방출형의 의약 제제
|
WO1996002269A1
(en)
*
|
1994-07-13 |
1996-02-01 |
Auckland Uniservices Limited |
Therapeutic method and compounds of use therein
|
CA2202879C
(en)
|
1994-10-21 |
2005-08-30 |
Bradford C. Van Wagenen |
Calcium receptor-active compounds
|
US6143718A
(en)
*
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
CA2246431A1
(en)
*
|
1996-01-19 |
1997-07-24 |
Board Of Regents, The University Of Texas System |
Recombinant expression of proteins from secretory cell lines
|
US6110707A
(en)
*
|
1996-01-19 |
2000-08-29 |
Board Of Regents, The University Of Texas System |
Recombinant expression of proteins from secretory cell lines
|
ES2201300T3
(es)
*
|
1996-05-01 |
2004-03-16 |
Nps Pharmaceuticals, Inc. |
Compuestos activos frente a receptores de iones inorganicos.
|
US5677279A
(en)
*
|
1996-12-16 |
1997-10-14 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating pain with amylin or agonists thereof
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7312196B2
(en)
*
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7101853B2
(en)
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
DE19725619A1
(de)
*
|
1997-06-17 |
1998-12-24 |
Fraunhofer Ges Forschung |
Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
|
US6821954B2
(en)
|
1997-09-18 |
2004-11-23 |
Auckland Uniservices Limited |
Compounds and uses thereof in treating bone disorders
|
AU5916298A
(en)
*
|
1998-01-09 |
1999-07-26 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
US6936584B1
(en)
|
1998-02-13 |
2005-08-30 |
Amylin Pharmaceuticals, Inc. |
Mixed amylin activity compounds
|
US6087334A
(en)
*
|
1998-08-21 |
2000-07-11 |
Amylin Pharmaceuticals, Inc. |
Anti-diabetic peptides
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US20030166561A1
(en)
*
|
1999-06-18 |
2003-09-04 |
Cooper Garth J. S. |
Peptide
|
WO2000078805A1
(en)
*
|
1999-06-18 |
2000-12-28 |
Protemix Corporation Limited |
Peptide having preptin functionality
|
WO2001000223A2
(en)
*
|
1999-06-25 |
2001-01-04 |
Minimed Inc. |
Multiple agent diabetes therapy
|
US7022674B2
(en)
*
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
WO2002024727A2
(en)
*
|
2000-09-19 |
2002-03-28 |
University Of Toronto |
New inhibitors of iapp fibril formation and uses thereof
|
WO2002067969A2
(en)
|
2001-02-21 |
2002-09-06 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
CN1617737A
(zh)
|
2001-11-26 |
2005-05-18 |
普罗特米克斯公司 |
用于使哺乳动物组织中的脂质水平正常化的组合物和方法
|
US20040038861A1
(en)
*
|
2001-11-26 |
2004-02-26 |
Cooper Garth J. S. |
Methods and compositions for normalizing lipid levels in mammalian tissues
|
ATE412421T1
(de)
*
|
2002-01-08 |
2008-11-15 |
Amylin Pharmaceuticals Inc |
Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
WO2004037168A2
(en)
*
|
2002-10-18 |
2004-05-06 |
Amylin Pharmaceuticals, Inc. |
Treatment of pancreatitis with amylin
|
US8008255B2
(en)
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
MXPA05013901A
(es)
*
|
2003-07-01 |
2006-03-09 |
Essentys Ab |
Uso de acido alfa-cetoglutarico para tratamiento de desnutricion o condicion de glucosa alta en plasma.
|
WO2006083254A1
(en)
|
2004-02-11 |
2006-08-10 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
US20080032915A1
(en)
*
|
2004-02-12 |
2008-02-07 |
Campina Nederland Holding B.V. |
Cysteine Rich Peptides for Improving Thiol Homeostasis
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
WO2007104786A1
(en)
|
2006-03-15 |
2007-09-20 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
AU2008297551A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a defensin peptide as a therapeutic agent
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
AU2008303925A1
(en)
*
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of insulin C-peptide, alone or in combination with GLP-1, as a therapeutic agent
|
MX2011009559A
(es)
|
2009-03-12 |
2012-01-12 |
Nordic Bioscience As |
Tratamiento de la diabetes y el sindrome metabolico.
|
CN102666570B
(zh)
*
|
2009-12-01 |
2015-12-02 |
诺沃—诺迪斯克有限公司 |
新的肽基α-羟基甘氨酸α-酰胺化裂合酶
|
TWI753471B
(zh)
|
2013-07-03 |
2022-01-21 |
美商艾爾德生物製藥股份有限公司 |
使用抗cgrp抗體之葡萄糖代謝的調節
|
WO2015196174A1
(en)
|
2014-06-20 |
2015-12-23 |
Greene Howard E |
Infusion delivery devices and methods
|
US10772556B2
(en)
|
2014-11-05 |
2020-09-15 |
Cláudio Afonso Ambrósio |
Method and system for monitoring and treating hypoglycemia
|
WO2018122278A1
(fr)
|
2016-12-27 |
2018-07-05 |
Adocia |
Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
MA49678A
(fr)
|
2017-07-27 |
2021-04-14 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
FR3083089A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
EP3723728A1
(fr)
|
2017-12-07 |
2020-10-21 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
TWI813604B
(zh)
|
2017-12-07 |
2023-09-01 |
法商阿道洽公司 |
包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
|
EP3740195A1
(fr)
|
2017-12-07 |
2020-11-25 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
MX2020005916A
(es)
|
2017-12-07 |
2020-10-19 |
Adocia |
Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
|
US11129877B2
(en)
|
2017-12-07 |
2021-09-28 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
|
FR3083085B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
US20190275108A1
(en)
|
2017-12-07 |
2019-09-12 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
|
FR3083086A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
FR3084586B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|